

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN

SEMAGLUTIDE

PRONUNCIATION

sem" a gloo' tide


THERAPEUTIC CLAIM

Treatment of type 2 diabetes

CHEMICAL NAMES

- Glycine, L-histidyl-2-methylalanyl-L- α -glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L- α -aspartyl-L-valyl-L-seryl-L-seryl-L-tyrosyl-L-leucyl-L- α -glutamylglycyl-L-glutaminyll-L-alanyl-L-alanyl-N⁶-[N-(17-carboxy-1-oxoheptadecyl-L- γ -glutamyl[2-(2-aminoethoxy)ethoxy]acetyl[2-(2-aminoethoxy)ethoxy]acetyl]-L-lysyl-L- α -glutamyl-L-phenylalanyl-L-isoleucyl-L-alanyl-L-tryptophyl-L-leucyl-L-valyl-L-arginylglycyl-L-arginyl-
- N^{6,26}-{18-[N-(17-carboxyheptadecanoyl)-L- γ -glutamyl]-10-oxo-3,6,12,15-tetraoxa-9,18-diazaoctadecanoyl}-[8-(2-amino-2-propanoic acid),34-L-arginine]human glucagon-like peptide 1(7-37)

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₁₈₇H₂₉₁N₄₅O₅₉

MOLECULAR WEIGHT

4114

TRADEMARK

None as yet

MANUFACTURER

Novo Nordisk

CODE DESIGNATION

NNC 0113-0217

CAS REGISTRY NUMBER

910463-68-2